<DOC>
	<DOCNO>NCT00799188</DOCNO>
	<brief_summary>Heart transplant recognize therapeutic strategy refractory heart failure . Its success however hamper severe cancer occurrence recurrence . The new m-tor inhibiting drug Sirolimus Everolimus show potential reduce incidence cancer animal model . They potent immunosuppressant , antiproliferative antiangiogenic drug . This open label randomized multicenter study aim evaluate beneficial antineoplastic effect Everolimus 159 heart transplant patient suffer recurrent skin cancer . Primary objective demonstrate reduction number new skin cancer . Secondary end point time recurrence , incidence non skin cancer , graft function follow switch ( include death ) , renal function evolution follow calcineurin inhibitor reduction withdrawal , Everolimus tolerance profile , scheme calcineurin inhibitor reduction management center .</brief_summary>
	<brief_title>CERTICOEUR : A Secondary Prevention Study Skin Cancers Heart Transplant Patients . Everolimus Versus Calcineurin Inhibitors Multicenter Trial</brief_title>
	<detailed_description>- Open label randomized Everolimus v reduction calcineurin inhibitor trial . 2:1 randomization design - October 10 , 2008 - 159 patient ( 106 everolimus v 53 calcineurin inhibitor reduction ) - 175 patient ( 117 vs 58 ) - X Not yet recruit 0 recruit 0 longer recruit - Number skin tumor per patient require surgery histology control within 2 year Within 2 year Follow : - New skin cancer - Number patient new skin cancer - Time recurrence - Number histology type skin cancer - Graft function ( include acute rejection , graft loss , death ) - Renal function evolution assess use Cockcroft creatinine clearance proteinuria - Adverse event serious adverse event - Non skin cancer ( Number diagnostic ) - Schemes calcineurin inhibitor reduction/withdrawal - Immune response assessment regulatory effector function blood situ T lymphocytes baseline follow immunosuppression switch</detailed_description>
	<mesh_term>Skin Neoplasms</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Calcineurin Inhibitors</mesh_term>
	<criteria>First orthotopic heart transplant 1st year No rejection within previous 6 Months Occurrence squamous cell carcinoma , basal cell carcinoma , situ carcinoma , Bowen disease , premalignant keratosis Recurrence skin cancer lead immunosuppressive regimen modification Removal skin lesion past three year Above 18 yr contraceptive drug applicable Informed consent give Health coverage ongoing Other non simultaneously transplant organ recent biopsy proven acute rejection Proteinuria &gt; 1g/l Ongoing infectious disease HIV positivity , Chronic active Hepatitis B C. Abnormal blood test : transaminase &gt; = 3UNL , Bilirubin &gt; 34 mmol.l , albumin &lt; 35 g/l , spontaneous INR &gt; 1,3 Hemoglobin &gt; = 8 g/dl , White Blood Count &lt; = 2 giga/l , platelet count &lt; = 50 giga/l Hypercholesterolemia &gt; = 9 mmol/l , hypertriglyceridemia &gt; = 8,5 mmol/l despite treatment History macrolid mTor inhibitor intolerance Previous cancer skin year prior enrollment Medical surgical condition unsuitable trial Breast feeding Positive pregnancy test Severe psychiatric disorder Communication language disability</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Cardiac Transplantation</keyword>
	<keyword>Skin cancer</keyword>
	<keyword>Everolimus</keyword>
</DOC>